Danaher Posts Fall in 1Q Earnings, Continues to Expects Lower Annual Sales
By Robb M. Stewart
Danaher continues to expect underlying sales will fall this year, though it said it had a good start to the year with improving order trends in its bioprocessing business.
The health-care and laboratory-supply company posted first-quarter earnings for the quarter ended Dec. 31 of $1.09 billion, or $1.45 a share, down from $1.45 billion, or $2.65 a share, a year earlier.
Excluding certain one-off items, Danaher logged adjusted earnings from continuing operations of $1.92 a share, beating the average Wall Street estimate of $1.72 a share
Sales for the first three months of the year fell 2.6% to $5.80 billion, but surpassed the $5.62 billion analysts expected.
For the second quarter, Danaher expects core revenue before items will be down mid-single digits on the same period last year. Full-year core sales are still expected to be down low-single digits, it said.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
April 23, 2024 06:46 ET (10:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase
-
After Earnings, Is Nio Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Lululemon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks